Tempus said today that it is partnering with the University of Pennsylvania’s Abramson Cancer Center to used next-generation sequencing-based genomic and transcriptomic data to determine which patients will respond positively to immunotherapies.
Launched in 2015, Tempus is building a business around offering genomic sequencing services and proprietary analytics to clinicians to help them devise more effective treatments for cancer patients who don’t respond to conventional therapies. Under the terms of the agreement, Tempus will sequence and analyze de-identified pancreatic and melanoma cancer data collected from Penn Medicine patients. It will then use its machine learning and bioinformatics solution to search for patterns in the data that can provide insights into which immunotherapies are likely to be effective for particular patient cohorts.
The agreement puts “cutting-edge technology into the hands of our physicians” and “enhances the resources they need to best serve their patients,” Chi Van Dang, director of the Abramson Cancer Center, said in a statement. “We are thrilled to collaborate with Tempus, a company that shares our commitment to research and innovation toward the advancement of patient care.”
Financial and other terms of the deal were not disclosed.
In October, Tempus signed an agreement with Rush University Medical Center to provide sequencing and analysis services to help advance its personalized cancer treatment efforts.